GENERAL
Sun Pharma Gets Global Ex-US, China Rights To LIB’s Lerodalcibep Drug
Sun Pharmaceutical Industries Ltd has entered into an exclusive licensing agreement with LIB Therapeutics Inc to commercialise and manufacture lerodalcibep worldwide, excluding the United States and China, strengthening its presence in the global cardiovascular medicines market. Lerodalcibep, marketed as Lyrokaul in the European Union, is a once-monthly PCSK9 inhibitor designed to lower low-density lipoprotein cholesterol […]
CW Bureau
·
Sep 28, 2026
GENERAL
Sun Pharma Receives Organon Shareholders Nod For $11.75-Bn Buy
Leading global pharmaceutical company Sun Pharmaceutical Industries Ltd has received shareholder approval from Organon & Co. for its proposed acquisition. The approval marks a key milestone towards completion of the transaction. Following the deal, Organon will become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA Inc., an indirect wholly owned subsidiary of Sun Pharma. […]
CW Bureau
·
Jul 24, 2026
GENERAL
Sun Pharma Bets On R&D, Compliance Upgrades To Speed Up Growth Engine
Sun Pharmaceutical Industries is sharpening its focus on research and development, regulatory compliance, and manufacturing capabilities as it targets high single-digit consolidated revenue growth in FY27, Chairman Dilip Shanghvi said during the company’s latest earnings call. The pharmaceutical major continues to invest heavily in strengthening both its global generics and innovative medicines businesses, with R&D […]
CW Bureau
·
May 30, 2026
